Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial

Clinical Endocrinology

Volumn 65, Issue 3, 2006, Pages 320-326

  Lucas, T ^a,c   Astorga, R ^b   Almeida Ruas, ^d   Paiva, ^d   Ribeiro, ^d   Alonso, ^e,aj   Lisbona, ^e   Ugena, ^e   Ballesteros, ^f   Cano, ^f,k   Perez ^f,ad,aj   Astorga, ^b   Leal, ^b   Venegas, ^b   Villamil, ^b   Garcia Hernandez ^b   Barberia ^g   Goni ^g   Menendez ^g   Blanco, ^h   Alvarez ^h,ar   Saavedra, ^h   Rubio, ^h   Borges, ⁱ   Horta, ⁱ   Cabezas Cerrato, ^j   Bernabeu, ^j   Garcia Rico ^k   Goday, ^k   Mauri, ^k   Puig, ^k   Corominas, ^k   Casanueva, ^l   Tome ^l   Peino ^l   Carvalho, ^m   Medina, ^m   Vinha, ^m   Catala ⁿ   Martinez ⁿ   Diaz Cadorniga ^o   Botas, ^o   Delgado, ^o,ag   Del Pozo, ^p   Dominguez ^q   Arman, ^q   Escobar Jimenez ^r   Torres, ^r   Munoz ^r   Esteva, ^s   Gonzalez ^s   Lopez ^s   Faure, ^t   Roche, ^t   Freijanes, ^u   Amado, ^u   Pazos, ^u   Otero, ^u   Pesquera, ^u   Gutierrez ^u   Garcia Mayor ^v   Paramo ^v   Gavilan ^w   Sillero, ^w   Rodriguez ^w   Hawkins, ^x   Ruiz Valdepenas ^x   Herrera, ^y   Gonzalo, ^y   Lara, ^y   Marazuela, ^z   Gomez Pan ^z   Mielgo, ^z   Jara, ^aa   Moreno, ^aa   Gargallo, ^aa   Garrido, ^aa   Lucas, ^c   Barcelo ^c   Estrada, ^c   Mato, ^ab   Gippini, ^ab   Solache, ^ab   Fernandez ^ab,ad   Monereo, ^ac   Pavon ^ac   Molina, ^ac,ag   Elviro, ^ac   Perosanz, ^ac   Morales, ^ad   Luna, ^ad   Luengo, ^ad   Moreiro, ^ae   Gomez ^ae   Garcia Fernandez ^ae   Masmiquel, ^ae   Urgeles ^ae   Fernandez Estivaria ^ae   Pereg Marcazaga, ^ae   Codina, ^ae   Obiols, ^af   Lecube, ^af   Pallardo, ^ag   Diez ^ag   Castro, ^ag   Pico ^ah   Boix, ^ah   Eleno, ^ah   Prieto, ^ai   Cacho, ^ai   Casal, ^ai   Salinas, ^aj   Soler, ^ak   Villabona, ^ak   Batista, ^ak   Tebar ^al   Liante, ^al   Tuson ^am   Martinez Faedo ^am   Rodrigo, ^am   Varela, ^an   Zurita, ^an   Vazquez ^ao   Gaztambide, ^ao   Vendrell, ^ap   Simon ^ap   Vidal Pardo, ^aq   Botana, ^aq   Matias Leralta ^aq   Vidal Vazquez ^ar   Cordido, ^ar   Isidro, ^ar   Vidal, ^as   Padros ^as   Cabanes, ^as   Pineda, ^at   Paino, ^at   Cendros ^at   Valles ^at   Obach, ^at   more..

^a Service of Endocrinology   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e Hospital del Aire   (Spain)

^f HOSPITAL DE LEÓN   (Spain)

^g Universidad Pública de Navarra   (Spain)

^h HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

ⁱ HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^j Instituto de Salud Carlos III   (Spain)

^k HOSPITAL DEL MAR   (Spain)

^l HOSPITAL DE CONXO   (Spain)

^m Hospital de S João   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^o HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^p HOSPITAL MÚTUA DE TERRASSA   (Spain)

^q HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^r HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^s HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^t HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^u HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^v HOSPITAL XERAL CÍES   (Spain)

^w HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^x HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^y Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^z HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^aa HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^ab Unidad Clínica de Conductas Adictivas   (Spain)

^ac HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^ad HOSPITAL INFANTA CRISTINA   (Spain)

^ae HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^af HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^ag HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^ah HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^ai HOSPITAL DE CABUEÑES   (Spain)

^aj HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^ak HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^al HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^am HOSPITAL ÁLVAREZ BUYLLA   (Spain)

^an HOSPITAL RAMÓN Y CAJAL   (Spain)

^ao HOSPITAL DE CRUCES   (Spain)

^ap HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^aq HOSPITAL XERAL CALDE   (Spain)

^ar HOSPITAL JUAN CANALEJO   (Spain)

^as Laboratorio de Analisis Clinicos   (Spain)

^at IPSEN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AUTOGEL;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACROMEGALY; ADULT; ARTICLE; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DYSPNEA; ERYTHEMA; FEMALE; FLATULENCE; GASTROINTESTINAL TOXICITY; HUMAN; INJECTION PAIN; INJECTION SITE REACTION; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARTICLE SIZE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN INDURATION;

ACROMEGALY; ADULT; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GELS; GROWTH HORMONE; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 33747374573     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02595.x     Document Type: Article

References (32)

1. Ikuyama, S., Nawata, H., Kato, K., Ibayashi, H. & Nakagaki, H. (1986) Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. Journal of Clinical Endocrinology and Metabolism, 62, 729-733.
2. Reubi, J. & Landolt, A. (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. Journal of Clinical Endocrinology and Metabolism, 68, 844-850.
3. Ayuk, J., Stewart, S., Stewart, P. & Sheppard, M. (2002) Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 4142-4146.
4. Sheppard, M.C. (2003) Primary medical therapy for acromegaly. Clinical Endocrinology, 58, 387-399.
5. Lucas, T., Astorga, R. & Catala, M. (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clinical Endocrinology, 58, 471-481.
6. Morange, I., De Boisvilliers, F., Chanson, P., Lucas, B., DeWailly, D., Catus, F., Thomas, F. & Jaquet, P. (1994) Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. Journal of Clinical Endocrinology and Metabolism, 79, 145-151.
7. Lancranjan, I., Bruns, C., Grass, P., Jaquet, P., Jervell, J., Kendall-Taylor, P., Lamberts, S.W., Marbach, P., Orskov, H., Pagani, G., Sheppard, M. & Simionescu, L. (1996) Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism, 45, 67-71.
8. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Laurberg, P., Pico, A.M., Valimaki, M. & Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99-104.
9. Cendros, J., Peraire, C., Troconiz, I. & Obach, R. (2005) Pharmacokinetics and population pharmacodynamic analysis of lanreotide autogel. Metabolism, 54, 1276-1281.
10. Ciccarelli, A., Daly, A. & Beckers, A. (2004) Lanreotide autogel for acromegaly: a new addition to the treatment armamentarium. Treatments in Endocrinology, 3, 77-81.
11. Lightman, S. (2002) Somatuline autogel: an extended release lanreotide formulation. Hospital Medicine, 63, 162-165.
12. Gutt, B., Bidlingmaier, M., Kretschmar, K., Dieterle, C., Steffin, B. & Schopohl, J. (2005) Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (lanreotide autogel). Experimental and Clinical Endocrinology and Diabetes, 113, 139-144.
13. Alexopoulou, O., Abrams, P., Verhelst, J., Poppe, K., Velkeniers, B., Abstract, R. & Maiter, D. (2004) Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR. European Journal of Endocrinology, 151, 317-324.
14. Ashwell, S.G., Bevan, J.S., Edwards, O.M., Harris, M.M., Holmes, C., Middleton, M.A. & James, R.A. (2004) The efficacy and safety of lanreotide autogel in patients with acromegaly previously treated with octreotide LAR. European Journal of Endocrinology, 150, 473-480.
15. Van Thiel, S.W., Romijn, J.A., Biermasz, N.R., Ballieux, B.E., Frolich, M., Smit, J.W., Corssmit, E.P., Roelfsema, F. & Pereira, A.M. (2004) Octreotide long-acting repeatable and lanreotide autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology, 150, 489-495.
16. Barbanoj, M., Antonijoan, R., Morte, A., Grinyo, J.M., Sola, R., Valles, J., Peraire, C., Cordero, J.A., Munoz, A., Jane, F. & Obach, R. (1999) Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. Clinical Pharmacology and Therapeutics, 66, 485-491.
17. CPMP (2001) Evaluation of medicines for human use. Note for guidance on the investigation of bioavailability and bioequivalence. London, The European Agency for the Evaluation of Medicinal Products, 26 July 2001.
18. Stewart, P.M. (2000) Current therapy for acromegaly. Trends in Endocrinology and Metabolism, 11, 128-132.
19. Abosch, A., Tyrrell, J.B., Lamborn, K.R., Hannegan, L.T., Applebury, C.B. & Wilson, C.B. (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism, 83, 3411-3418.
20. Bates, A.S., Van't Hoff, W., Jones, J.M. & Clayton, R.N. (1993) An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine, 86, 293-299.
21. Orme, S.M., McNally, R.J., Cartwright, R.A. & Belchetz, P.E. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
22. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. & Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95-102.
23. Swearingen, B., Barker, F.G. 2nd, Katznelson, L., Biller, B.M., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P.M. & Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419-3426.
24. Baldelli, R., Colao, A., Razzore, P., Jaffrain-Rea, M.L., Marzullo, P., Ciccarelli, E., Ferretti, E., Ferone, D., Gaia, D., Camanni, F., Lombardi, G. & Tamburrano, G. (2000) Two-year follow-up of acromegalic patients treated with slow-release lanreotide (30 mg). Journal of Clinical Endocrinology and Metabolism, 85, 4099-4103.
25. Verhelst, J.A., Pedroncelli, A.M., Abstract, R., Montini, M., Vandeweghe, M.V., Albani, G., Maiter, D., Pagani, M.D., Legros, J.J., Gianola, D., Bex, M., Poppe, K., Mockel, J. & Pagani, G. (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. European Journal of Endocrinology, 143, 577-584.
26. Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S. & Rabinowitz, D. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465-4473.
27. Culler, M.D., Taylor, J.E. & Moreau, J.P. (2002) Somatostatin receptor subtypes: targeting functional and therapeutic specificity. Annales D'Endocrinologie, 63, 2S5-2S12.
28. Jaquet, P., Saveanu, A., Gunz, G., Fina, F., Zamora, A.J., Grino, M., Culler, M.D., Moreau, J.P., Enjalbert, A. & Ouafik, L.H. (2000) Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism, 85, 781-792.
29. Feenstra, J., de Herder, W.W., ten Have, S.M., van den Beld, A.W., Feelders, R.A., Janssen, J.A. & van der Lely, A.J. (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, 365, 1644-1646.
30. Marzullo, P., Ferone, D., di Somma, C., Pivonello, R., Filippella, M., Lombardi, G. & Colao, A. (1999) Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary, 1, 115-120.
31. Caron, P., Bex, M., Cullen, D.R., Feldt-Rasmussen, U., Pico Alfonso, A.M., Pynka, S., Racz, K., Schopohl, J., Tabarin, A. & Valimaki, M.J. (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide autogel. Clinical Endocrinology, 60, 734-740.
32. Heron, I., Thomas, F., Dero, M., Gancel, A., Ruiz, J.M., Schatz, B. & Kuhn, J.M. (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 76, 721-727.